Business Context and Reporting Period
Company: Relmada Therapeutics, Inc. (RLMD)
Filing Type: Form 8-K (Current Report)
Date of Report: March 24, 2025
Event: Entry into a Material Definitive Agreement (Exclusive License Agreement) with Trigone Pharma, Ltd. for the fixed-dose formulation of gemcitabine and docetaxel (NDV-01).
Key Financial Metrics and Transaction Terms
This filing details a strategic licensing agreement rather than periodic financial results. Key financial terms include:
- Upfront Consideration: $3,500,000 non-refundable, non-creditable cash payment.
- Equity Issuance: 3,017,420 restricted shares of Relmada common stock issued to Trigone.
- Development Milestones: Maximum potential aggregate of $105,000,000 upon achievement of specified events.
- Commercial Milestones: Maximum potential aggregate of $95,000,000 upon achievement of specified events.
- Royalties: 3% on net sales of Licensed Products in the Territory (Worldwide excluding India, Israel, and South Africa).
- Minimum Spend Requirement: Relmada must expend at least $5,000,000 per calendar year (starting Jan 1, 2026) on R&D/commercialization to avoid termination.
Material Changes and Agreements
The primary material change is the acquisition of an exclusive, royalty-bearing license for NDV-01. Additional material terms include:
- Ownership: Relmada retains sole ownership of all new data, know-how, and inventions generated.
- Responsibilities: Relmada is solely responsible for all clinical/non-clinical development, manufacturing, and regulatory compliance costs.
- Sublicensing: Relmada may grant sublicenses but must pay Trigone 20% of any consideration received, subject to a floor ensuring Trigone receives no less than the original agreement terms.
- Termination: Relmada may terminate without cause upon 30 days' notice. Trigone may terminate if Relmada fails to meet the minimum annual spend requirement.
- Lock-Up: Trigone agreed to a 12-month lock-up period on the issued shares and agreed to vote shares as recommended by Relmada's board.
Guidance, Risks, and Contingencies
Management Commentary: The filing incorporates a press release (Exhibit 99.1) announcing the agreement but does not provide specific forward-looking financial guidance or revenue projections in this text.
Risks and Contingencies:
- Performance Risk: Failure to spend $5,000,000 annually on the program could result in termination of the license.
- Financial Obligation: Significant contingent liabilities exist via potential milestone payments totaling up to $200,000,000 and ongoing royalty obligations.
- Equity Dilution: The issuance of over 3 million shares represents a dilutive event for existing shareholders.
Investor Verification Checklist
- Verify the current cash balance and liquidity position to confirm the ability to fund the $3.5M upfront payment and the $5M annual minimum spend requirement.
- Review the full text of the License Agreement (Exhibit 10.1, if available in the full filing) for specific definitions of "development" and "commercialization" milestones.
- Assess the impact of the 3,017,420 share issuance on fully diluted share count and earnings per share.
- Confirm the status of NDV-01 clinical trials and the timeline for potential regulatory approval to gauge the likelihood of milestone payments.
- Check for any existing debt covenants that might be triggered by the equity issuance or the new contingent liabilities.